Armata Pharmaceuticals, Inc. (ARMP)
| Previous close | 1.9500 |
| Open | 1.9200 |
| Bid | 0.8000 x 1300 |
| Ask | 0.0000 x 2200 |
| Day's range | 1.8701 - 2.2000 |
| 52-week range | 1.8400 - 6.4600 |
| Volume | |
| Avg. volume | 9,576 |
| Market cap | 69.398M |
| Beta (5Y monthly) | -0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0070 |
| Earnings date | 09 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
- Zacks
Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- PR Newswire
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.
